RYBREVANT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for RYBREVANT (RYBREVANT).
RYBREVANT (amivantamab-vmjw) is a bispecific antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal-epithelial transition factor (MET) receptor, blocking ligand binding and inducing receptor degradation. It also mediates antibody-dependent cellular cytotoxicity (ADCC) against tumor cells overexpressing EGFR and MET.
| Metabolism | RYBREVANT is a monoclonal antibody, expected to be degraded into small peptides and amino acids via general protein catabolic pathways. No specific metabolic enzymes are involved. |
| Excretion | RYBREVANT (amivantamab) is a monoclonal antibody that undergoes catabolism to small peptides and amino acids. No specific excretion studies have been conducted; endogenous IgG is eliminated primarily via intracellular catabolism. Fecal excretion is minimal (<1%). |
| Half-life | Terminal half-life is approximately 11.3 days (range 4.2–30.4 days) at the recommended dose. This supports a dosing interval of every 2 weeks after initial weekly loading doses. |
| Protein binding | Amivantamab is a monoclonal antibody; protein binding is not typically applicable. As an IgG1, it may bind to FcRn and other proteins, but specific binding % is not defined. Minimal non-specific binding to plasma proteins is expected. |
| Volume of Distribution | Volume of distribution at steady state is approximately 3.86 L (range 2.49–5.60 L). This low Vd is consistent with distribution primarily in the vascular and interstitial spaces, typical of monoclonal antibodies. |
| Bioavailability | RYBREVANT is administered intravenously, thus bioavailability is 100%. |
| Onset of Action | Intravenous administration: clinical response (e.g., tumor shrinkage) may be observed after 2–4 cycles (6–12 weeks), based on clinical trial data. |
| Duration of Action | Duration of action corresponds to the dosing interval; steady-state concentrations are achieved by approximately 4 weeks with the weekly loading schedule. The effect persists throughout the treatment course until disease progression or unacceptable toxicity. |
RYBREVANT (amivantamab-vmjw) is administered intravenously. The recommended dose is 1050 mg (weight <80 kg) or 1400 mg (weight ≥80 kg) once weekly for 4 weeks, then every 2 weeks thereafter. Administer as a 60-minute infusion for the first dose, 40-minute infusion for the second dose, and 30-minute infusion for subsequent doses.
| Dosage form | INJECTABLE |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl 30-89 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min) or end-stage renal disease. |
| Liver impairment | No dose adjustment recommended for mild hepatic impairment (Child-Pugh A). Not studied in moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy in pediatric patients have not been established. No recommended dose. |
| Geriatric use | No specific dose adjustment recommended for elderly patients. Of the 258 patients in the clinical trial, 41% were aged 65 years or older. No overall differences in safety or efficacy were observed compared to younger patients. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for RYBREVANT (RYBREVANT).
| Breastfeeding | No data on presence in human milk, effects on breastfed infant, or milk production. Because of potential for serious adverse reactions (e.g., EGFR inhibition in infant), advise women not to breastfeed during treatment and for 3 months after last dose. M/P ratio: unknown. |
| Teratogenic Risk | Based on its mechanism of action (EGFR inhibition) and animal studies, RYBREVANT (amivantamab-vmjw) is expected to cause fetal harm when administered to pregnant women. In animal reproduction studies, EGFR inhibition has been associated with embryolethality and teratogenicity. There are no adequate human data. Advise pregnant women of potential risk to fetus. First trimester: Highest risk; avoid use due to potential for major congenital malformations. Second and third trimesters: Continued risk, including potential for fetal growth restriction, oligohydramnios, and fetal renal impairment. |
■ FDA Black Box Warning
None.
| Serious Effects |
None.
| Precautions | ["Infusion-related reactions (IRRs): Occurred in 66% of patients, requiring premedication and monitoring.","Interstitial lung disease (ILD)/pneumonitis: Observed in 4% of patients; withhold or permanently discontinue if confirmed.","Dermatologic adverse reactions: Rash (89%) and paronychia (45%); manage with topical steroids, antibiotics, or dose modifications.","Venous thromboembolic events (VTE): Occurred in 9% of patients; consider anticoagulation in high-risk patients.","Ocular toxicity: Keratitis (2%) and other eye disorders; monitor for symptoms.","Growth restriction in animal studies: Embryo-fetal harm potential; use effective contraception during treatment and for 3 months after last dose."] |
Loading safety data…
| Fetal Monitoring | Monitor pregnant women exposed to RYBREVANT for evidence of adverse fetal effects. Consider serial ultrasound assessments for fetal growth and amniotic fluid volume. Postnatal monitoring for renal function in infants is recommended if exposure occurs during second/third trimester. |
| Fertility Effects | Based on animal studies, RYBREVANT may impair female fertility. No specific human data; EGFR signaling is involved in reproductive function. In females, potential for reduced fertility due to effects on ovulation and implantation. In males, no definitive data, but possible impact on spermatogenesis. |